CANCELLED: Treatment of Opioid Use Disorder: Waiver Qualifying - Michigan - Monday, October 25, 2021
- Registration Closed
Host: Michigan Opioid Collaborative
Monday, October 25, 2021 | 8:00 am - 5:00 pm ET
Virtual Live Course
Overview
This 8-hour virtual live course covers treating opioid use disorder by using interactive, case-based learning to teach evidence-based practices and also provides the required education needed to obtain the waiver to prescribe buprenorphine. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.
The target audience for this introductory-level course includes: Physicians, Nurse Practitioners, Physician Assistants, Certified Nurse Midwives, Certified Registered Nurse Anesthetists, and Clinical Nurse Specialists who wish to obtain a waiver to prescribe buprenorphine in an office-based setting for opioid use disorder.
This activity addresses the following ACGME Competencies: Patient Care and Medical Knowledge.
Learning Objectives
Upon completion, learners will be able to:
- Identify, assess and diagnose patients with opioid use disorder while considering severity, chronicity, individual characteristics, and psychiatric and medical comorbidities
- Develop an individualized, patient-centered treatment plan including negotiating treatment goals by evaluating appropriate medication- and psychosocial-based treatment options
- Monitor progress and modify treatment plan based on patient needs and progress toward treatment goals
- Implement best practices for office systems including team-based care to support treatment with medications for opioid use disorder
- Examine misconceptions, stigma, and complexities (bioethical, social, clinical, public health) associated with opioid use disorder and the use of medications to treat opioid use disorder
Registration Rates
| ASAM Learner Type | Rate |
| ASAM Member | $0 |
| Non-Member | $0 |
| Associate Member | $0 |
| Resident Member* | $0 |
| Student Member* | $0 |
*Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.
Membership Question? Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.
Refunds & Cancellations
All ASAM e-Learning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or e-Learning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.
Registration Deadline: 10/25/2021
Instructions
- Click on the Contents tab to begin this activity.
- Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
- Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM e-Learning Center, clicking Dashboard, and clicking Transcript/Achievements.
Need Assistance?
For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org
ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.
Andrew King
MD
Originally trained in emergency medicine and later, medical toxicology in Pittsburgh, I became board certified in addiction medicine in 2020 through ABPM. Prior to becoming board certified, my clinical and research focus has pivoted to taking care of patients with OUD in the emergency department. I developed a screening and treatment protocol with warm handoff capabilities to outside facilities for patients identified in the ED with OUD at the Detroit Medical Center. We have also developed an inpatient addiction medicine consultation service that takes care of patients with OUD in the hospital and helps with linkage, if necessary. I have also joined the psychiatry department and working at the Tolan Park Park Opioid treatment program where I treat with methadone, buprenorphine, and naltrexone.
Community Foundations for Southeast Michigan-
Consultant/Advisory Board
Sheba Sethi
MD
University of Michigan
Sheba Sethi, MD works as an addiction medicine consultant and primary care doctor at Packard Health. She is board certified in Internal Medicine and is a member of American Society of Addiction Medicine (ASAM). She graduated from Drexel University College of Medicine in 2016. She did her internal medicine residency training at Montefiore Medical Center Primary Care and Social Medicine program in the Bronx, NY. She is passionate about social medicine or the study of how social, economic, environmental and epidemiologic conditions impact health and disease. Her clinical interests involve treatment of substance use disorders as well as care of vulnerable populations.
No relevant disclosures
Jonathan Morrow
MD, PhD
Jonathan Morrow, M.D., Ph.D. received his B.S. in Biological Sciences from the University of Southern California, and his M.D. and Ph.D. in Neuroscience from the University of Michigan. Dr. Morrow went on to complete his residency training in Adult Psychiatry at the University of Michigan, and subsequently joined the faculty of the University of Michigan as an Assistant Professor of in 2011. He provides medication management and other clinical care to patients through the University of Michigan Addiction Treatment Services. His clinical interests include treatment of co-occurring psychiatric disorders such as addiction and post-traumatic stress disorder (PTSD). The Morrow lab uses behavioral, pharmacological, immunohistochemical, and neurosurgical techniques to identify and manipulate specific neural circuits that show individual differences relevant to multiple psychiatric disorders, including both addiction and PTSD.
No relevant disclosures
CME, CE, CEU and Other Credit Types
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NAADAC, the Association for Addiction Professionals
This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.
California Association for Drug/Alcohol Educators (CAADE)
This educational program is approved by CAADE: #CP40 999 1222.
California Association of DUI Treatment Centers (CADTP)
This educational program is approved by CADTP: #205.
California Consortium of Addiction Programs and Professionals (CCAPP)
This educational program is approved by CCAPP: #OS-20-330-1222.
Continuing Education Credits (CEUs)
Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.
In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include mitigating all possible relevant financial relationships with ineligible companies for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
Key:
Complete
Next
Failed
Available
LockedHow to Apply for a Waiver
Physicians
- Fill out the Waiver Notification Form on SAMHSA’s website.
- Upload a copy of your training certificate(s) on the Waiver Notification Form.
SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.
Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.
If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.
Other Approved Prescribers
Apply
NPs and PAs may upload copies of their training certificates on the Waiver Notification Form. NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.
These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.
SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number.
Qualifications
To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete no less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.
Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.
Overview of Legislation
Physicians
The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.
Nurse Practitioners & Physician Assistants
On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.
To qualify, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete not less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD
HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.
NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:
- 24-Hour Buprenorphine Curriculum Collaborative with the American Association of Nurse Practitioners (AANP) and the American Academy of Physician Assistants (AAPA)
- Clinical Tools, Inc
- Provider's Clinical Support System for Medication-Assisted Treatment (PCSS-MAT)
Acknowledgements
The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior, Inc.
